論文・技術情報追加のお知らせ

1. Evaluation of the post-marketing safety of eculizumab from 2007 to 2025: A real-world pharmacovigilance study and signal analysis based on the FAERS database.

FAERS解析でエクリズマブの安全性を系統的評価し新規有害事象シグナルを特定

対象DB：FAERS

2. Adverse events associated with third-generation cephalosporins: Analysis of the FDA adverse event reporting system database.

FAERS解析で第3世代セファロスポリンの有害事象傾向と代表的副作用を特定

対象DB：FAERS

3. Gaps in the detection of drug-drug interactions between antipsychotic and cardiometabolic medications: a multisource analysis.

抗精神病薬と心代謝薬の薬物相互作用を体系的に解析しDDI検出精度を評価

対象DB：CVAR,FAERS

4. A Real-World Pharmacovigilance Study of Fruquintinib Based on the FDA Adverse Event Reporting System (FAERS) Database.

FAERS解析でフルキンチニブの新規有害事象と発現時期を特定

対象DB：FAERS

5. Drug-related adverse events in people with dementia - Statistical data from the FDA adverse event reporting system.

FAERS解析で認知症患者の有害事象特徴と薬剤別クラスタを特定

対象DB：FAERS

6. Nivolumab in gastric cancer with liver metastasis complicated by immune-mediated hepatitis: a case report and FAERS database analysis.

ニボルマブ誘発性肝炎症例とFAERS解析でICI肝障害を年齢別比較

対象DB：FAERS

7. Comparative Analysis of Ocular Adverse Events Associated with Aflibercept 8 mg and Faricimab: A Global Population-Based Study Across 65 Countries.

FAERS解析でアフリベルセプト2/8mgとファリシマブの眼有害事象を比較

対象DB：FAERS

8. Sex-stratified pharmacovigilance of gastrointestinal events associated with first-line smoking-cessation medicines: Insights from the FAERS database.

FAERS解析で禁煙補助薬の性差による消化器有害事象を比較

対象DB：FAERS

9. Systemic Toxicity With Use of Apraclonidine Ophthalmic Drops in Pediatric Patients.

FAERS等解析で小児アプラクロニジン点眼の全身毒性を報告

対象DB：FAERS

10. Drug-induced osteoporosis/osteopenia: a pharmacovigilance analysis using the FDA Adverse Event Reporting System database.

FAERS解析で薬剤性骨粗鬆症・骨減少症の主要リスク薬を特定

対象DB：FAERS

11. Drug-associated serotonin syndrome in elderly patients: a comprehensive disproportionality analysis based on the FAERS database.

FAERS解析で高齢者における薬剤性セロトニン症候群関連薬を特定

対象DB：FAERS

12. Pegylated liposomal doxorubicin-induced hand-foot syndrome in a patient with breast cancer: Case report and FAERS database analysis.

PLD投与後の手足症候群症例とFAERS解析で蒸気系アントラサイクリン比較

対象DB：FAERS

13. Oral anticoagulants and gastrointestinal bleeding: pharmacovigilance insights from the FDA adverse event reporting system database.

FAERS解析で経口抗凝固薬関連消化管出血リスクを系統評価

対象DB：FAERS

14. Risk of pulmonary fungal infections associated with biologics: a FAERS database disproportionality analysis.

FAERS解析で生物学的製剤使用と肺真菌感染リスク増加確認

対象DB：FAERS

15. Real-world feasibility of co-administration of RSV, COVID-19, and influenza vaccines in older adults: a VAERS-based analysis.

VAERS解析でRSV・COVID-19・インフル同時接種の良好な安全性確認

対象DB：FAERS,VAERS

16. Post-marketing safety assessment of Tyrvaya: A real-world pharmacovigilance analysis based on the FDA Adverse Event Reporting System.

FAERS解析でバレニクリン点鼻薬の新規有害事象シグナル確認

対象DB：FAERS

17. Exploration of adverse event profiles for glofitamab: A disproportionality analysis using the FDA adverse event reporting system.

FAERS解析でゴロフィタマブにサイトカイン放出症候群シグナル確認

対象DB：FAERS

18. Comparative Analysis of Adverse Drug Reactions Between Oritavancin Diphosphate and Oritavancin-HPbetaCD Using FAERS Data.

FAERS解析でオリタバンシン製剤間の安全性差異を確認

対象DB：FAERS

19. Post-market surveillance data demonstrate high mortality associated with enfortumab vedotin skin toxicity, not worsened by immune checkpoint inhibitors or corticosteroids.

市販後監視でエンホルツマブ皮膚毒性による高死亡率確認

対象DB：FAERS

20. Pharmacokinetic prediction and dosage adjustment of enoxaparin administration in pregnant women with renal insufficiency: a FAERS-PBPK modeling study.

FAERS解析とPBPK解析で腎障害妊婦のエノキサパリン減量指針を提示

対象DB：FAERS

21. Risk Factors for Drug-Induced Acute Generalized Exanthematous Pustulosis(AGEP) from 2004 to 2024: A Real-World Study Based on the FAERS.

FAERS解析でAGEP高リスク薬17種特定し抗菌薬等が主要因と判明

対象DB：FAERS

22. Pregnancy-Related Adverse Events with Tyrosine Kinase Inhibitor Use in Chronic Myeloid Leukemia: A FAERS Pharmacovigilance Analysis (2001-2024).

FAERS解析でイマチニブが妊娠関連有害事象と有意に関連

対象DB：FAERS

23. Safety of COMT-inhibitors in parkinson's disease: a phase-IV comparative study on adverse events of Tolcapone, Entacapone and Opicapone.

FAERS解析でエンタカポンがCOMT阻害薬中最も安全と判明

対象DB：FAERS

24. Anti-Osteoporotic Medication-Related Jaw Osteonecrosis: A Descriptive Analysis of the European EudraVigilance Database.

欧州EV解析で抗骨粗鬆症薬関連顎骨壊死の特徴を記述評価

対象DB：EudraVigilance

25. Tremelimumab Plus Durvalumab in Advanced Hepatocellular Carcinoma Treatment: A Pharmacovigilance Comparative Analysis Between Eudravigilance and HIMALAYA Study.

実臨床でデュルバルマブ＋トレメリムマブに免疫関連有害事象増加

対象DB：EudraVigilance

26. Respiratory Disorders Associated with Antibody-Drug Conjugates: A Combined Analysis of the French and the WHO Pharmacovigilance Databases.

ADCで間質性肺疾患など呼吸器有害事象の新シグナル確認

対象DB：FPVD,VigiBase

27. Potential utility of the new ISTH overt DIC scoring system for the mortality risk assessment of patients with sepsis, hematopoietic neoplasms, and solid cancers: a nation-wide database study in Japan.

ISTH新DICスコア2025が敗血症等で予後予測に有用と確認

対象DB：JMDC

28. Regional and Seasonal Analysis of Electroconvulsive Therapy Utilization in Japan: A Nationwide Population-Based Cohort Study Using Receipt Data (2014-2022).

日本でECT施行に地域格差が顕著で公平な提供体制が課題

対象DB：NDB

29. Precision medicine in type 2 diabetes: targeting SGLT2 inhibitor treatment for kidney protection.

SGLT2阻害薬腎保護効果を個別予測する新モデルを開発

対象DB：CPRD

30. The Effect of Use of Tricyclic Antidepressants or Serotonin-Norepinephrine Reuptake Inhibitors Versus Selective Serotonin Reuptake Inhibitors on the Risk of Urinary Tract Infection Among People With Multiple Sclerosis: A Nested Case-Control Study.

多発性硬化症でTCA・SNRI使用はSSRI比でUTI増加せず

対象DB：CPRD

31. Temporal relationship between severe mental illness and neurological conditions in a UK primary care cohort.

重度精神疾患患者で多くの神経疾患有病率が有意に高い

対象DB：CPRD

32. Among people who use heroin, tobacco smoking and illegal drugs cause a similar number of premature deaths.

ヘロイン使用者の早死因の約4分の1が喫煙と薬物

対象DB：CPRD

33. Prevalence of living alone with dementia and other progressive neurological conditions: findings from primary care data in England.

認知症など神経変性疾患患者の約4割が独居で支援格差懸念

対象DB：CPRD

34. Serotonin reuptake inhibiting antidepressants: A trigger for visual snow syndrome?

HPI2剤で新規有害事象シグナルと性差をFAERS解析

対象DB：CVAR